Genomic Valley Biotech Reports Q1 FY26 Results, Announces Key Appointments
Genomic Valley Biotech Limited (GVBL) released Q1 FY26 results, showing a 31.56% decrease in revenue to Rs. 6,16,000 and an 80.67% drop in net profit to Rs. 2,46,531 compared to Q1 FY25. The company appointed M/s. SBR & Co. LLP as Secretarial Auditors for 2025-2030, Mr. Navjyoti Kumar Jha as Internal Auditor for FY 2025-26, and re-appointed Mr. Yogesh Agrawal as Chairman & Managing Director for five years from September 7, 2025.
*this image is generated using AI for illustrative purposes only.
Genomic Valley Biotech Limited (GVBL) has released its unaudited financial results for the first quarter ended June 30, 2025, alongside several key leadership appointments. The company's Board of Directors approved these matters during a meeting held on August 7, 2025.
Financial Performance
GVBL reported a significant decline in both revenue and profit for Q1 FY26 compared to the same period last year:
| Particulars (in Rs.) | Q1 FY26 | Q1 FY25 | % Change |
|---|---|---|---|
| Revenue from Operations | 6,16,000.00 | 9,00,000.00 | -31.56 |
| Net Profit | 2,46,531.00 | 12,75,903.00 | -80.67 |
The company's revenue from operations decreased by 31.56% year-over-year, while net profit saw a substantial drop of 80.67%.
Key Appointments
The Board made several important appointments during the meeting:
Secretarial Auditors
M/s. SBR & Co. LLP, Company Secretaries (LLP No. AAO-9057), has been appointed as the Secretarial Auditors for the financial years 2025-2030. The firm, established in 2019, is based in Navi Mumbai with a branch office in Ghaziabad and has over 6 years of experience.
Internal Auditor
Mr. Navjyoti Kumar Jha has been appointed as the Internal Auditor for FY 2025-26. Mr. Jha brings 25 years of experience and holds a Bachelor of Commerce degree.
Chairman & Managing Director
Mr. Yogesh Agrawal has been re-appointed as Chairman & Managing Director for a period of five years, effective September 7, 2025. Mr. Agrawal, aged 62, is a Chartered Accountant with 35 years of business experience. He holds 14,27,000 equity shares in the company and is one of its promoters.
Additional Information
- The Board meeting commenced at 3:30 PM and concluded at 4:30 PM on August 7, 2025.
- The financial results were reviewed by the Audit Committee and approved by the Board of Directors.
- The company's statutory auditors have carried out a limited review of the financial results.
Genomic Valley Biotech continues to operate under the leadership of Mr. Yogesh Agrawal, who has been associated with the company since September 7, 2015. The company's performance in the coming quarters will be closely watched by investors and stakeholders, given the significant decline in revenue and profit during Q1 FY26.
Historical Stock Returns for Genomic Valley Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.64% | -2.65% | -15.16% | -50.89% | -69.53% | +63.71% |
17
